SCHEMBL1767795

SCHEMBL1767795

Cc1cccnc1-c1ccc2nc(N)c(I)cc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 6/20 0.49
CTSD P07339 2/20 0.49
CYP2A6 P11509 1/20 0.41
KDR P35968 3/20 0.40
LCK P06239 1/20 0.40
JAK3 P52333 1/20 0.40
MAPK14 Q16539 1/20 0.40
NOS3 P29474 1/20 0.40
NOS1 P29475 1/20 0.40
NOS2 P35228 1/20 0.40
ADORA2A P29274 2/20 0.39
ABL1 P00519 4/20 0.39
SRC P12931 3/20 0.39
PIK3CD O00329 2/20 0.39
EGFR P00533 2/20 0.39
HCK P08631 2/20 0.39
PIK3CA P42336 2/20 0.39
PIK3CB P42338 2/20 0.39
MTOR P42345 2/20 0.39
PIK3CG P48736 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5496119 0.78 LCK (0.66) BACE1CTSDCYP2A6KDRLCK
SCHEMBL1768085 0.73 BACE1 (0.54) BACE1CTSDKDRABL1SRC
SCHEMBL14266198 0.71 ABL1 (0.52) CYP2A6MAPK14ADORA2AABL1SRC
SCHEMBL1767886 0.71 BACE1 (0.51) BACE1CTSDKDRABL1SRC
SCHEMBL3975427 0.69 CYP2A6 (0.56) CYP2A6NOS3NOS1NOS2NPC1
SCHEMBL7229215 0.68 CYP2A6 (0.56) CYP2A6NOS3NOS1NOS2EGFR
SCHEMBL4358659 0.68 BACE1 (0.39) BACE1CTSDCYP2A6KDRLCK
SCHEMBL2660051 0.67 JAK2 (0.55) KDRJAK3DYRK1A
SCHEMBL10094661 0.66 GRM1 (0.51) CYP2A6KDRMAPK14ADORA2AABL1
SCHEMBL12818129 0.65 CYP2A6 (0.51) CYP2A6ABL1SQOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822485-B2 Amino heteroaryl compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2014-09-02 US disclosed
US-20130018064-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use AMGEN INC. (US) 2013-01-17 US disclosed
EP-2504330-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE Amgen Inc. (US) 2012-10-03 EP disclosed
WO-2011063272-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018064-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use BACE1, BACE2, APP BACE1 1/4885CTSD 828/4885CYP2A6 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.